Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million

Evaxion Biotech ( (EVAX) ) has issued an update.

On December 10, 2025, Evaxion Biotech A/S filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs), each representing fifty ordinary shares, with an aggregate offering price of up to $45,527,824. This filing is part of their Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, and it updates previous prospectuses to facilitate the sale of ADSs. This strategic financial move aims to bolster Evaxion’s capital, potentially enhancing its market position and operational capabilities in the biotechnology sector.

The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by strong technical indicators and positive earnings call highlights, including a significant deal with MSD and promising clinical data. However, financial challenges such as persistent net losses and reliance on debt weigh down the score. The valuation remains unattractive due to a negative P/E ratio and lack of dividend yield.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion Biotech A/S is a company based in Denmark, operating in the biotechnology industry. The company focuses on developing vaccines and immunotherapies, leveraging its proprietary AI technology to create personalized treatments. Its market focus includes addressing infectious diseases and cancer through innovative biotechnological solutions.

Average Trading Volume: 1,629,441

Technical Sentiment Signal: Sell

Current Market Cap: $39.67M

For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.